Ebola breakthrough? new trial aims to stop virus after exposure
NCT ID NCT06841614
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 22 times
Summary
This study tests whether giving a combination of a vaccine (Ervebo) and an antibody drug (Inmazeb) right after exposure to Ebola can prevent the disease better than the vaccine alone. It involves 160 people who have had close contact with an Ebola patient, such as touching their body fluids or caring for them. Participants are randomly assigned to receive either the vaccine alone or the vaccine plus the antibody, and are monitored for 21 days to see if they develop Ebola.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBOLA VIRUS DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guinea Centre for Research and Training in Infectious Diseases (CERFIG)
Conakry, Guinea
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Institute for Biomedical Research (INRB)
Kinshasa, Democratic Republic of the Congo
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Public Health Institute of Liberia
Monrovia, Liberia
Contact Email: •••••@•••••
-
University of Sierra Leone College of Medicine and Allied Health Sciences
Freetown, Sierra Leone
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.